BR9509997A - Antagonista de taquiquinina - Google Patents
Antagonista de taquiquininaInfo
- Publication number
- BR9509997A BR9509997A BR9509997A BR9509997A BR9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A BR 9509997 A BR9509997 A BR 9509997A
- Authority
- BR
- Brazil
- Prior art keywords
- tachykinin antagonist
- tachykinin
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
| PCT/EP1995/004910 WO1996018643A1 (en) | 1994-12-13 | 1995-12-12 | Tachykinin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9509997A true BR9509997A (pt) | 1997-12-30 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509997A BR9509997A (pt) | 1994-12-13 | 1995-12-12 | Antagonista de taquiquinina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (pt) |
| JP (1) | JPH10511935A (pt) |
| AR (1) | AR001332A1 (pt) |
| AU (1) | AU4343796A (pt) |
| BR (1) | BR9509997A (pt) |
| CA (1) | CA2204130A1 (pt) |
| CO (1) | CO4700289A1 (pt) |
| CZ (1) | CZ179097A3 (pt) |
| FI (1) | FI971685A (pt) |
| HU (1) | HUT77002A (pt) |
| IL (1) | IL116323A0 (pt) |
| NO (1) | NO972526L (pt) |
| PE (1) | PE38997A1 (pt) |
| PL (1) | PL320217A1 (pt) |
| SK (1) | SK74697A3 (pt) |
| TR (1) | TR199501568A2 (pt) |
| WO (1) | WO1996018643A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| WO1998015277A2 (en) * | 1996-10-07 | 1998-04-16 | Merck Sharp & Dohme Limited | Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents |
| WO2000048623A1 (en) | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| KR101412339B1 (ko) | 2004-07-15 | 2014-06-25 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도 |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| CN101495184A (zh) | 2005-07-15 | 2009-07-29 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用 |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CA2717509A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| US8518907B2 (en) | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Application Discontinuation
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
-
1997
- 1997-04-18 FI FI971685A patent/FI971685A/fi not_active Application Discontinuation
- 1997-06-03 NO NO972526A patent/NO972526L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK74697A3 (en) | 1997-11-05 |
| CA2204130A1 (en) | 1996-06-20 |
| HUT77002A (hu) | 1998-03-02 |
| AU4343796A (en) | 1996-07-03 |
| IL116323A0 (en) | 1996-03-31 |
| JPH10511935A (ja) | 1998-11-17 |
| NO972526D0 (no) | 1997-06-03 |
| CZ179097A3 (en) | 1997-10-15 |
| NO972526L (no) | 1997-06-03 |
| FI971685A0 (fi) | 1997-04-18 |
| CO4700289A1 (es) | 1998-12-29 |
| FI971685A (fi) | 1997-08-13 |
| WO1996018643A1 (en) | 1996-06-20 |
| PL320217A1 (en) | 1997-09-15 |
| EP0797583A1 (en) | 1997-10-01 |
| PE38997A1 (es) | 1997-10-02 |
| MX9703957A (es) | 1997-09-30 |
| TR199501568A2 (tr) | 1996-07-21 |
| AR001332A1 (es) | 1997-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9509997A (pt) | Antagonista de taquiquinina | |
| EE9600186A (et) | Neurokiniini (tahhüülkiniini) antagonistid | |
| PT805813E (pt) | Antagonistas de vasopressina triciclicos | |
| FI955927A (fi) | Substituoidut 1H-imidatsolit | |
| DE69534718D1 (de) | Substituierte 9-alkyladenine | |
| DK0824098T3 (da) | 4-Hydroxy-piperidinderivater | |
| BR9710600A (pt) | Barreira acÚstica | |
| ATE232526T1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
| BR9710601A (pt) | Barreira acÚstica | |
| NO964172L (no) | Virvelindusert vibrasjonssperre | |
| DE69732715D1 (de) | Tachykinin antagoniste | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| BR9503042A (pt) | Composto de polialquilpiperidina | |
| NO975541D0 (no) | 4-hydroksy-piperidinderivater | |
| BR9509559A (pt) | Azolilulsolfonilfeniluracilas substituídas | |
| DE59602637D1 (de) | Heftvorrichtung | |
| ID17945A (id) | Lemari es | |
| KR950027351U (ko) | 반목 항타장치 | |
| DE59510274D1 (de) | Substituierte biphenyloxazoline | |
| KR970702876A (ko) | 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists) | |
| DK0964867T3 (da) | Tachykininantagonister | |
| KR950033383U (ko) | 가드레일 | |
| KR960003039U (ko) | 개선된 파마로이 | |
| IT1286743B1 (it) | Barriera antiacustica | |
| PT9246T (pt) | Barreira antiencandeamento polivalente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law |